Publicaciones en colaboración con investigadores/as de Hospital Universitario Central de Asturias (13)

2020

  1. Epigenetic downregulation of TET3 reduces genome-wide 5hmC levels and promotes glioblastoma tumorigenesis

    International Journal of Cancer, Vol. 146, Núm. 2, pp. 373-387

  2. Global hyperactivation of enhancers stabilizes human and mouse naive pluripotency through inhibition of CDK8/19 Mediator kinases

    Nature Cell Biology, Vol. 22, Núm. 10, pp. 1223-1238

  3. No genome-wide DNA methylation changes found associated with medium-term reduced graphene oxide exposure in human lung epithelial cells

    Epigenetics, Vol. 15, Núm. 3, pp. 283-293

2019

  1. Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment

    Nucleic Acids Research, Vol. 47, Núm. 10, pp. 5016-5037

  2. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations

    The Journal of clinical endocrinology and metabolism, Vol. 104, Núm. 11, pp. 5673-5692

2018

  1. Epigenetic dysregulation of TET2 in human glioblastoma

    Oncotarget, Vol. 9, Núm. 40, pp. 25922-25934

  2. SDHC promoter methylation, a novel pathogenic mechanism in parasympathetic paragangliomas

    Journal of Clinical Endocrinology and Metabolism, Vol. 103, Núm. 1, pp. 295-305

2017

  1. Cisplatin resistance in cell models evaluation of metallomic and biological predictive biomarkers to address early therapy failure

    Metallomics, Vol. 9, Núm. 5, pp. 564-574

2016

  1. The effect of exposure to nanoparticles and nanomaterials on the mammalian epigenome

    International Journal of Nanomedicine, Vol. 11, pp. 6297-6306

2013

  1. Long-term biomonitoring of breast cancer patients under adjuvant chemotherapy: the comet assay as a possible predictiv

    Mutagenesis, Vol. 28, Núm. 1, pp. 39-48

2011

  1. Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: A phase Ib study

    International Journal of Gynecological Cancer, Vol. 21, Núm. 3, pp. 478-485

2007

  1. Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas

    Cancer Chemotherapy and Pharmacology, Vol. 59, Núm. 2, pp. 251-259

2004

  1. Phase I clinical trial of fixed-dose rate infusional gemcitabine and dacarbazine in the treatment of advanced soft tissue sarcoma, with assessment of gemcitabine triphosphate accumulation

    Cancer, Vol. 101, Núm. 10, pp. 2261-2269